[go: up one dir, main page]

EA201890142A1 - Замещенные пиримидиновые обратные ингибиторы bmi-1 - Google Patents

Замещенные пиримидиновые обратные ингибиторы bmi-1

Info

Publication number
EA201890142A1
EA201890142A1 EA201890142A EA201890142A EA201890142A1 EA 201890142 A1 EA201890142 A1 EA 201890142A1 EA 201890142 A EA201890142 A EA 201890142A EA 201890142 A EA201890142 A EA 201890142A EA 201890142 A1 EA201890142 A1 EA 201890142A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bmi
substituted pyrimidine
reduce
inhibit
function
Prior art date
Application number
EA201890142A
Other languages
English (en)
Other versions
EA035349B1 (ru
Inventor
Чан-Сун Ли
Рамиль Байазитов
Лянсянь Цао
Томас У. Дэвис
У Ду
Жунган Лю
Йоунг-Чоон Моон
Стивен Д. Пэджет
Хунюй Жэнь
Надя Сидоренко
Ричард Джеральд Уайлде
Original Assignee
ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПиТиСи ТЕРАПЬЮТИКС, ИНК. filed Critical ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Publication of EA201890142A1 publication Critical patent/EA201890142A1/ru
Publication of EA035349B1 publication Critical patent/EA035349B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Oncology (AREA)

Abstract

В настоящей заявке описаны аминзамещенные обратные пиримидиновые соединения и их формы, которые ингибируют функцию и снижают уровень B-клеточного специфического сайта интеграции 1 вируса мышиного лейкоза Молони (Bmi-1), и способы их использования для ингибирования функции Bmi-1 и снижения уровня Bmi-1 для лечения рака, опосредованного Bmi-1.
EA201890142A 2012-11-21 2013-11-21 ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1 EA035349B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21

Publications (2)

Publication Number Publication Date
EA201890142A1 true EA201890142A1 (ru) 2018-06-29
EA035349B1 EA035349B1 (ru) 2020-05-29

Family

ID=50776672

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201590992A EA031405B1 (ru) 2012-11-21 2013-11-21 Замещенные пиримидиновые обратные ингибиторы bmi-1
EA201890142A EA035349B1 (ru) 2012-11-21 2013-11-21 ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201590992A EA031405B1 (ru) 2012-11-21 2013-11-21 Замещенные пиримидиновые обратные ингибиторы bmi-1

Country Status (32)

Country Link
US (3) US10428050B2 (ru)
EP (1) EP2922828B1 (ru)
JP (3) JP6412503B2 (ru)
KR (4) KR102455889B1 (ru)
CN (2) CN111423417B (ru)
AR (1) AR093579A1 (ru)
AU (1) AU2013348009C1 (ru)
BR (1) BR112015011760B1 (ru)
CA (1) CA2892045C (ru)
CL (1) CL2015001377A1 (ru)
CR (1) CR20150294A (ru)
CU (1) CU24387B1 (ru)
DK (1) DK2922828T3 (ru)
EA (2) EA031405B1 (ru)
EC (1) ECSP15019948A (ru)
ES (1) ES2821529T3 (ru)
HK (1) HK1215032A1 (ru)
IL (2) IL238871B (ru)
MA (1) MA38208B1 (ru)
MX (2) MX2015006469A (ru)
NI (1) NI201500072A (ru)
NZ (2) NZ746607A (ru)
PE (1) PE20151413A1 (ru)
PH (1) PH12015501130B1 (ru)
PL (1) PL2922828T3 (ru)
PT (1) PT2922828T (ru)
SA (1) SA517381847B1 (ru)
SG (2) SG11201503982XA (ru)
TW (1) TWI623531B (ru)
UA (1) UA118094C2 (ru)
WO (1) WO2014081906A2 (ru)
ZA (1) ZA201503642B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031405B1 (ru) 2012-11-21 2018-12-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые обратные ингибиторы bmi-1
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3019480B1 (en) * 2013-07-11 2020-05-06 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015030847A1 (en) 2013-08-30 2015-03-05 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
JP7001593B2 (ja) 2015-08-11 2022-01-19 コグノア， インコーポレイテッド 人工知能およびユーザ入力を用いて発達進度を判定するための方法および装置
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
CN108602775B (zh) * 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
EP3539033B1 (en) 2016-11-14 2024-10-02 Cognoa, Inc. Methods and apparatus for evaluating developmental conditions and providing control over coverage and reliability
JP7324709B2 (ja) * 2017-02-09 2023-08-10 コグノア，インク． デジタル個別化医療のためのプラットフォームとシステム
US11458126B2 (en) 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
BR112021002630A2 (pt) 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
BR112021013913A2 (pt) * 2019-01-15 2021-09-21 Ptc Therapeutics, Inc. Método para tratar uma leucemia mieloide aguda
EA202192117A1 (ru) * 2019-02-28 2021-11-23 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способ лечения множественной миеломы
MX2021010906A (es) 2019-03-11 2021-10-01 Ptc Therapeutics Inc Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas.
WO2020198065A1 (en) 2019-03-22 2020-10-01 Cognoa, Inc. Personalized digital therapy methods and devices
WO2020198705A1 (en) * 2019-03-27 2020-10-01 Ptc Therapeutics, Inc. Combinations useful in a method for treating sarcoma
CA3135929A1 (en) * 2019-04-02 2020-10-08 Hinova Pharmaceuticals Inc. Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators
EP4294513A1 (en) 2021-02-19 2023-12-27 Mevion Medical Systems, Inc. Gantry for a particle therapy system

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (ru) * 1973-09-20 1977-11-30 Delalande Sa
DE69530989T2 (de) * 1994-08-13 2004-05-19 Yuhan Corp. Neue pyrimidinderivate und verfahren zu ihrer herstellung
IN188411B (ru) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6498165B1 (en) 1999-06-30 2002-12-24 Merck & Co., Inc. Src kinase inhibitor compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
ES2306671T3 (es) 1999-10-07 2008-11-16 Amgen Inc. Inhibidores de triazina quinasa.
AU7922900A (en) 1999-10-27 2001-05-08 Novartis Ag Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
KR20030024659A (ko) * 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
CN100355751C (zh) 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
JP4105949B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
PT1330452E (pt) 2000-09-20 2009-01-22 Ortho Mcneil Pharm Inc Derivados de pirazina como moduladores de tirosina-cinases
WO2002047690A1 (en) * 2000-12-12 2002-06-20 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
WO2002048148A2 (en) 2000-12-15 2002-06-20 Glaxo Group Limited Pyrazolopyridine derivatives
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
ES2316546T3 (es) 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
EP1975620A3 (en) 2001-03-02 2008-12-24 GPC Biotech AG Three hybrid assay system
CA2450555A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
CA2452603A1 (en) 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003075828A2 (en) * 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
DE60331187D1 (de) 2002-05-23 2010-03-25 Cytopia Res Pty Ltd Kinaseinhibitoren
BRPI0312288B8 (pt) 2002-06-28 2021-05-25 Nippon Shinyaku Co Ltd derivados de amidas
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (en) 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
AU2003301302A1 (en) 2002-10-15 2004-05-04 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
NZ546058A (en) 2004-01-12 2010-09-30 Ym Biosciences Australia Pty Benzimidazole and other fused ring derivatives as selective janus kinase inhibitors
JP2007520558A (ja) 2004-02-04 2007-07-26 スミスクライン・ビーチャム・コーポレイション キナーゼ阻害剤として有用なピリミジノン化合物
JP4937112B2 (ja) * 2004-03-30 2012-05-23 バーテックス ファーマシューティカルズ インコーポレイテッド Ｊａｋおよび他のプロテインキナーゼの阻害剤として有用なアザインドール
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
NZ561000A (en) 2005-02-28 2010-01-29 Japan Tobacco Inc Novel aminopyridine compound with Syk inhibitory activity
UY29414A1 (es) 2005-03-10 2006-10-02 Bayer Pharmaceuticals Corp Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
JP2009541268A (ja) 2006-06-22 2009-11-26 ビオヴィトルム・アクチボラゲット（プブリクト） Ｍｎｋキナーゼ阻害剤としてのピリジンおよびピラジン誘導体
CA2665398A1 (en) * 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
US7968556B2 (en) * 2006-10-19 2011-06-28 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and methods of treatment therewith
JP2010514689A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物
CL2008000197A1 (es) 2007-01-26 2008-08-01 Smithkline Beecham Corp Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
WO2008099210A2 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
UY31048A1 (es) 2007-04-25 2008-11-28 Astrazeneca Ab Nuevos compuestos de pirimidina y usos de los mismos
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
US8415358B2 (en) 2007-09-17 2013-04-09 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
EA020777B1 (ru) 2007-11-16 2015-01-30 Инсайт Корпорейшн 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
EA018459B1 (ru) 2007-12-07 2013-08-30 Новартис Аг Производные пиразола и их применение в качестве ингибиторов циклинзависимых киназ
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
EP2271631B1 (en) 2008-04-22 2018-07-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EP2306836B1 (en) * 2008-07-01 2016-09-07 PTC Therapeutics, Inc. Bmi-1 protein expression modulators
WO2010016005A1 (en) 2008-08-06 2010-02-11 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
US8618099B2 (en) * 2008-09-02 2013-12-31 Ataxion, Inc. Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
WO2010061903A1 (ja) * 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
EP2397479A4 (en) 2009-02-12 2012-08-01 Astellas Pharma Inc HETERO RING DERIVATIVE
WO2010110685A2 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimddinyl and 1,3,5-triazinyl benzimtoazole sulfonamides and their use in cancer therapy
CA2763624A1 (en) 2009-05-27 2010-12-02 Abbott Laboratories Pyrimidine inhibitors of kinase activity
TW201102387A (en) 2009-06-08 2011-01-16 Medicinova Inc Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
SI2442809T1 (sl) * 2009-06-17 2017-01-31 Vertex Pharmaceuticals Incorporated Inhibitorji replikacije virusov gripe
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2011008830A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyrazine inhibitors of kinases
CA2767089A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
MX2012008083A (es) 2010-01-12 2012-08-15 Ab Science Inhibidores de triazol y oxazol quinaza.
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
EP2606126B1 (en) * 2010-08-19 2016-05-18 F.Hoffmann-La Roche Ag Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs)
AU2011303978B2 (en) 2010-09-13 2014-07-03 Novartis Ag Triazine-oxadiazoles
US20140088056A1 (en) * 2010-09-28 2014-03-27 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
US9090593B2 (en) * 2010-12-09 2015-07-28 Amgen Inc. Bicyclic compounds as Pim inhibitors
US9850227B2 (en) 2011-02-25 2017-12-26 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
WO2013004332A1 (en) * 2011-07-07 2013-01-10 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EA031405B1 (ru) * 2012-11-21 2018-12-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые обратные ингибиторы bmi-1
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
MX2021010906A (es) * 2019-03-11 2021-10-01 Ptc Therapeutics Inc Forma de un compuesto que tiene biodisponibilidad mejorada y formulaciones de las mismas.

Also Published As

Publication number Publication date
AU2013348009A1 (en) 2015-06-04
CN111423417B (zh) 2022-11-15
KR20220016305A (ko) 2022-02-08
KR20150086345A (ko) 2015-07-27
JP2016504290A (ja) 2016-02-12
US10428050B2 (en) 2019-10-01
ZA201503642B (en) 2020-10-28
TW201427972A (zh) 2014-07-16
MA38208B1 (fr) 2021-12-31
US20220064150A1 (en) 2022-03-03
UA118094C2 (uk) 2018-11-26
CL2015001377A1 (es) 2016-02-19
PH12015501130B1 (en) 2023-01-27
PT2922828T (pt) 2020-10-12
AU2013348009C1 (en) 2019-08-08
CN111423417A (zh) 2020-07-17
EA031405B1 (ru) 2018-12-28
KR20210088740A (ko) 2021-07-14
ECSP15019948A (es) 2016-01-29
US20200024260A1 (en) 2020-01-23
NZ708909A (en) 2019-11-29
ES2821529T3 (es) 2021-04-26
HK1215032A1 (zh) 2016-08-12
JP6412503B2 (ja) 2018-10-24
CA2892045A1 (en) 2014-05-30
EA035349B1 (ru) 2020-05-29
CN104918919A (zh) 2015-09-16
PH12015501130A1 (en) 2015-08-03
US11180483B2 (en) 2021-11-23
TWI623531B (zh) 2018-05-11
MX2015006469A (es) 2015-10-29
SG11201503982XA (en) 2015-06-29
IL238871A0 (en) 2015-07-30
WO2014081906A3 (en) 2014-07-17
IL265253A (en) 2019-05-30
KR102356487B1 (ko) 2022-02-08
KR102275676B1 (ko) 2021-07-12
AU2013348009B2 (en) 2018-05-17
KR20220143164A (ko) 2022-10-24
JP2020055815A (ja) 2020-04-09
SA517381847B1 (ar) 2021-07-17
WO2014081906A2 (en) 2014-05-30
KR102455889B1 (ko) 2022-10-17
NI201500072A (es) 2016-01-18
CA2892045C (en) 2022-05-31
CU24387B1 (es) 2019-03-04
CR20150294A (es) 2015-08-20
SG10201600149VA (en) 2016-02-26
CU20150053A7 (es) 2015-11-27
AR093579A1 (es) 2015-06-10
BR112015011760B1 (pt) 2022-12-06
PE20151413A1 (es) 2015-10-23
EP2922828A4 (en) 2016-07-27
PL2922828T3 (pl) 2020-12-28
US20150315182A1 (en) 2015-11-05
BR112015011760A2 (pt) 2017-07-11
EP2922828A2 (en) 2015-09-30
EA201590992A1 (ru) 2015-11-30
EP2922828B1 (en) 2020-07-08
NZ746607A (en) 2019-11-29
MX2021009892A (es) 2021-09-14
JP6617186B2 (ja) 2019-12-11
JP2019031509A (ja) 2019-02-28
DK2922828T3 (da) 2020-08-31
IL238871B (en) 2019-03-31
JP6918898B2 (ja) 2021-08-11

Similar Documents

Publication Publication Date Title
EA201890142A1 (ru) Замещенные пиримидиновые обратные ингибиторы bmi-1
EA201690502A1 (ru) Замещенные пиримидиновые ингибиторы bmi-1
JO3515B1 (ar) مثبطات fgfr4 بيريميدين
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
MX380907B (es) Compuestos útiles como inhibidores de cinasa.
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201690268A1 (ru) Замещенные производные хиназолин-4-она
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
EA201492056A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
MA40076A (fr) Inhibiteurs de syk
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
MX2016014559A (es) Compuestos para el tratamiento de cancer.
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
ECSP17010482A (es) Novedosas pirimidinas 2,5-sustituidas
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.
MX376059B (es) Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk).
EA201691130A1 (ru) Средства и способы противодействия миелопролиферативным или лимфопролиферативным расстройствам
MX2015009678A (es) Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4).
EA201992557A1 (ru) Противоопухолевые соединения
EA201990239A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM